Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644478 | 0.88 | HDAC3 (0.32) | L3MBTL1NPC1RAB9ATDP1ALDH1A1 | |
| SCHEMBL4645455 | 0.85 | ALDH1A1 (0.31) | L3MBTL1ALDH1A1 | |
| SCHEMBL4644261 | 0.84 | PPARD (0.31) | PPARDPPARA | |
| SCHEMBL5176741 | 0.77 | CTSG (0.42) | L3MBTL1PPARDPPARAALDH1A1 | |
| SCHEMBL4641590 | 0.74 | GPR35 (0.31) | — | |
| SCHEMBL4643410 | 0.73 | CYP2A6 (0.34) | — | |
| SCHEMBL4644391 | 0.72 | HDAC3 (0.32) | L3MBTL1ALDH1A1 | |
| SCHEMBL9812562 | 0.68 | L3MBTL1 (0.50) | L3MBTL1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL5178565 | 0.67 | LMNA (0.43) | NPC1RAB9ATDP1PPARDPPARA | |
| SCHEMBL4644772 | 0.66 | CYP2A6 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1298130-B1 | 3-HYDROXYMETHYLBENZO B THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | TEIJIN PHARMA LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6774245-B2 | SELECTIVE HYDROGENATION OF 7-SUBSTITUTED-3-HYDROXYMETHYL-BENZO(B)THIOPHENE DERIVATIVE; CYCLIZATION, SULFIDING | TEIJIN LIMITED (JP) | 2004-08-10 | — | — | US | disclosed |
| US-20030191325-A1 | 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation | TEIJIN LIMITED (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1298130-A1 | 3-HYDROXYMETHYLBENZO B THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | TEIJIN LIMITED (JP) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191325-A1 | 3-Hydroxymethylbenzo[b]thiophene derivatives and process for their preparation | TST, SULT1E1, CYP4B1 | STING1 4207/4885L3MBTL1 839/4885NPC1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.